Boston Scientific Corporation reports positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system to the Promus element stent system.
The data were presented at EuroPCR 2014 by Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. The primary clinical and angiographic endpoints of this non-inferiority study have already been published.
“The Synergy stent three-year results from the EVOLVE trial continue to show promise with respect to safety and efficacy,” said Meredith. “Target lesion revascularisation remains very low, at a rate of 1.1%, while there is no stent thrombosis in the Synergy full-dose arm at three years. The EVOLVE clinical data support the hypothesis that this novel bioabsorbable polymer stent technology could allow for improved healing over durable polymer drug-eluting stent.”
Boston Scientific has expanded its commercial launch of the Synergy stent system in Europe and in select markets in Asia. It features an ultrathin abluminal bioabsorbable drug/polymer coating technology which eliminates long-term polymer exposure. In addition to reducing restenosis, the Synergy stent system may also offer faster and more complete vessel healing after stent implantation, potentially reducing the duration of post-procedure dual antiplatelet therapy.
The Synergy stent system is an investigational device in the USA and Japan, and is not available for sale in those countries.
